Integra LifeSciences (IART) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Integra LifeSciences (NASDAQ: IART):

• 11/13/2025 – Integra LifeSciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Integra LifeSciences was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/3/2025 – Integra LifeSciences had its “hold” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $13.00 price target on the stock, down previously from $15.00.
• 10/31/2025 – Integra LifeSciences had its price target lowered by analysts at Citigroup Inc. from $12.00 to $11.00. They now have a “sell” rating on the stock.
• 10/31/2025 – Integra LifeSciences had its price target raised by analysts at JPMorgan Chase & Co. from $12.00 to $13.00. They now have an “underweight” rating on the stock.
• 10/15/2025 – Integra LifeSciences was given a new $15.00 price target on by analysts at Truist Financial Corporation. They now have a “hold” rating on the stock.
• 10/8/2025 – Integra LifeSciences had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Integra LifeSciences had its “sell” rating reaffirmed by analysts at Citigroup Inc.. They now have a $12.00 price target on the stock, up previously from $10.00.
• 9/27/2025 – Integra LifeSciences had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Integra LifeSciences

In related news, Director Jeffrey A. Graves bought 9,000 shares of the firm’s stock in a transaction on Wednesday, November 5th. The stock was acquired at an average cost of $11.35 per share, for a total transaction of $102,150.00. Following the purchase, the director owned 41,086 shares in the company, valued at approximately $466,326.10. This represents a 28.05% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.54% of the company’s stock.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.